Ellogon AI
Ellogon.AI assists medical experts in selecting the right patient for cancer immunotherapy through fast and accurate quantification of relevant biomarkers using a breakthrough deep learning approach. Their CE certified solution, EIDOSTM, is fully integrated into existing medical treatment protocols, leveraging AI to optimize the selection process of patients who will benefit from immunotherapy. The company has established partnerships with leading institutions like the Netherlands Cancer Institute and the University of Amsterdam, enhancing their data access and AI expertise. With a focus on personalized medicine, Ellogon.AI aims to improve cancer treatment outcomes by providing actionable insights from complex medical data, positioning itself as a leader in the intersection of AI and healthcare.
Ellogon AI
Ellogon.AI assists medical experts in selecting the right patient for cancer immunotherapy through fast and accurate quantification of relevant biomarkers using a breakthrough deep learning approach. Their CE certified solution, EIDOSTM, is fully integrated into existing medical treatment protocols, leveraging AI to optimize the selection process of patients who will benefit from immunotherapy. The company has established partnerships with leading institutions like the Netherlands Cancer Institute and the University of Amsterdam, enhancing their data access and AI expertise. With a focus on personalized medicine, Ellogon.AI aims to improve cancer treatment outcomes by providing actionable insights from complex medical data, positioning itself as a leader in the intersection of AI and healthcare.
TL;DR
Focus: AI-driven computational pathology for immunotherapy patient selection
Flagship product: EIDOS — CE certified solution for biomarker quantification
Headquarters: Amsterdam, The Netherlands
Founded: 2019
Notable partners/grants: Amsterdam UMC, Netherlands Cancer Institute, University of Amsterdam; KWF research grant
Convertible note led by Innovatiefonds Noord-Holland
Company Overview
Problem Domain
Computational pathology and biomarker-driven patient selection for immunotherapy
Founded
2019
Industry
Biotechnology
Tech Stack
Funding Track Record
Most recently listed round per available profiles
Investor Signal
“Participation from regional investors and research grants including Innovatiefonds Noord-Holland; Dealroom lists an Early VC round (~€1.0M, Mar 2024) with investors including UvA - AMC - HvA Ventures and ROM InWest”